Brand: XYPROL-T
Composition: Each tablet contains Metoprolol Tartrate IP 50 mg
Dosage form: Tablet
Usage: Treatment of high blood pressure
Category: Anti Cardiovascular Drugs
Therapeutic category: Cardiovascular Agent / Antihypertensive (Beta Blocker)
SKU: Metoprolol Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Metoprolol Tartrate Tablets IP is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufacturer: Healthy Life Pharma Pvt. Ltd. (WHO-GMP certification requires verification)
Exporter: Healthy Inc (Star Export House status requires verification)
Metoprolol Tartrate Tablets IP 50 mg contain a cardioselective beta-1 adrenergic blocker used in the management of hypertension and selected other cardiovascular conditions. Metoprolol reduces heart rate, cardiac workload and myocardial oxygen demand. Its beta-1 selectivity is dose-dependent and does not eliminate respiratory risks.
The supplied product listing identifies XYPROL-T as a brand of Metoprolol Tartrate Tablets IP 50 mg. Healthy Life Pharma Pvt. Ltd. is named as manufacturer and Healthy Inc as exporter. Certification, facility methods, export status and market authorizations should be confirmed from current documents.
| Product name | Metoprolol Tartrate Tablets |
|---|---|
| Brand | XYPROL-T |
| Confirmed strength | 50 mg |
| Composition | Each tablet contains Metoprolol Tartrate IP 50 mg |
| Dosage form | Tablet (immediate-release tartrate formulation; verify final approved label) |
| Standard | IP as supplied; USP/BP compliance not independently confirmed |
| Therapeutic class | Cardioselective beta blocker / antihypertensive |
| Usage | High blood pressure and other approved cardiovascular indications |
| SKU | Metoprolol Tablets |
| Packaging and shelf life | Confirm against approved pack and stability data |
Strength verification: Only 50 mg is confirmed in the supplied composition statements. The 25 mg and 100 mg strengths mentioned in descriptive copy require separate product-label confirmation.
Production of immediate-release metoprolol tartrate tablets requires appropriate control of raw materials, blending, compression, content uniformity and disintegration/dissolution. Specific direct-compression, wet-granulation, HPMC-coating and dedicated equipment claims should be supported by validated manufacturing records.
Packaging must be selected on the basis of stability and moisture-protection requirements of the approved formulation. No particular blister or bottle configuration is verified by the supplied composition.
Finished-product release should be supported by applicable pharmacopoeial and registered specifications, including identification, assay, content uniformity, dissolution, related substances, and stability. Specific universal assay ranges or release percentages should not be advertised without the actual monograph and approved specification.
WHO-GMP status, certificate of analysis, stability period and regulatory approvals should be checked before publication or supply.
Metoprolol selectively antagonizes cardiac beta-1 receptors at usual therapeutic concentrations, reducing sympathetic stimulation, heart rate and contractility. It is used for hypertension, angina and certain post-myocardial-infarction treatment regimens, subject to local approved labeling and clinical assessment.
Important formulation distinction: Metoprolol tartrate immediate-release tablets are not the same product as metoprolol succinate extended-release tablets. Conversion or substitution requires clinician review. The immediate-release tartrate product must not be represented as a proven substitute for extended-release succinate in heart-failure regimens.
Market registration may require CTD/ACTD documents, manufacturing licenses, approved labels, analytical specifications, stability evidence, certificates of analysis and country-specific documentation. Availability of COPP, FSC, WHO-GMP certification, serialization and FOB/CIF shipping terms must be verified directly with the supplier.
Q: What is the confirmed tablet strength?
A: Metoprolol Tartrate IP 50 mg per tablet. Other strengths mentioned in marketing text have not been confirmed by the supplied labels.
Q: Is XYPROL-T a metoprolol tartrate brand?
A: The supplied composition identifies XYPROL-T Tablets as Metoprolol Tartrate IP 50 mg.
Q: Is this identical to Toprol-XL?
A: No. Toprol-XL contains extended-release metoprolol succinate, whereas this product is described as metoprolol tartrate tablets.
Q: Can treatment be stopped suddenly?
A: Abrupt discontinuation can worsen angina and precipitate serious cardiac events in susceptible patients. Dose reduction should be supervised by a prescriber.
Use only as directed by a registered medical practitioner. Dose and frequency vary with the indication, blood pressure, heart rate, coexisting illness and approved product label. Do not use a generic maximum dose or a post-heart-attack dosing schedule without an indication-specific prescription. Metoprolol tartrate is commonly taken with or immediately after meals, as directed by the product label.
Common effects: Fatigue, dizziness, low blood pressure and slow heart rate. Major precautions: Bradycardia, atrioventricular conduction disturbances, cardiogenic shock and decompensated heart failure require careful assessment; certain conditions are contraindications under product labeling.
Respiratory disease: Beta-1 selectivity does not remove bronchospasm risk in patients with asthma or other bronchospastic disease. Diabetes: Beta blockers may mask warning signs such as tachycardia during hypoglycemia. Withdrawal: Avoid sudden cessation, especially in coronary artery disease. Monitor pulse and blood pressure, and discuss potential interactions with other heart-rate-lowering medicines.
Store in the original packaging according to the approved product label, protected from unsuitable heat, moisture and light. The suggested below-25°C condition and 36-month shelf life must be confirmed from the finished product's approved stability information. Keep out of reach of children.